Escitalopram in specific phobia: Results of a placebo-controlled pilot trial. Journal of Psychopharmacology, 22, 157-161

Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC, USA.
Journal of Psychopharmacology (Impact Factor: 3.59). 04/2008; 22(2):157-61. DOI: 10.1177/0269881107080796
Source: PubMed


To assess the efficacy and safety of escitalopram in treating specific phobia.
The study was performed in an academic medical center. Adults meeting DSM-IV criteria for specific phobia were randomly assigned to 12 weeks of double-blind treatment with escitalopram or placebo. Efficacy measures included the Main Phobia Scale (MPS), the Marks Fear Questionnaire (FQ) and the Clinical Global Impressions of Improvement (CGI-I) scale. Data were collected between September 2002 and September 2004.
Of 13 subjects enrolled, 12 returned for at least one post-randomization visit and were included in the intent to treat sample. Response rates on the various subscales of the MPS and the FQ ranged from 20 to 80% for escitalopram, compared to 0-43% with placebo. Rates of response using the CGI-I scale were 60% for escitalopram and 29% for placebo, with a strong between treatment effect in favor of the drug at week 12 (effect-size = 1.13). Using the last observation carried forward, no statistically significant treatment differences were found. The drug was well tolerated.
Treatment response was consistently greater for escitalopram than for placebo, with strong effects observed in favor of the drug. However, treatment differences on the primary outcome measures were not significant in this under-powered pilot study. Escitalopram may hold promise as a treatment for specific phobia and larger randomized controlled trials are needed.

Download full-text


Available from: Jonathan Davidson, Sep 15, 2014
  • Source
    • "Alamy et al reported results from a pilot study with only 12subjects, that escitalopram may hold promise as a treatment for specific phobia but that larger randomized controlled trials are needed since the pilot study was underpowered (Alamy et al. 2008). Benjamin et al found in a study of 11 subjects that paroxetine appeared to be significantly superior to a placebo, which led them to conclude that this therapeutic option deserves further examination in a larger trial (Benjamin et al. 2000). "

    Full-text · Article ·
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: In this report, which is an update of a guideline published in 2002 (Bandelow et al. 2002, World J Biol Psychiatry 3:171), recommendations for the pharmacological treatment of anxiety disorder, obsessive-compulsive disorder (OCD) and post-traumatic stress disorder (PTSD) are presented. Since the publication of the first version of this guideline, a substantial number of new randomized controlled studies of anxiolytics have been published. In particular, more relapse prevention studies are now available that show sustained efficacy of anxiolytic drugs. The recommendations, developed by the World Federation of Societies of Biological Psychiatry (WFSBP) Task Force for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-traumatic Stress Disorders, a consensus panel of 30 international experts, are now based on 510 published randomized, placebo- or comparator-controlled clinical studies (RCTs) and 130 open studies and case reports. First-line treatments for these disorders are selective serotonin reuptake inhibitors (SSRIs), serotonin-noradrenaline reuptake inhibitors (SNRIs) and the calcium channel modulator pregabalin. Tricyclic antidepressants (TCAs) are equally effective for some disorders, but many are less well tolerated than the SSRIs/SNRIs. In treatment-resistant cases, benzodiazepines may be used when the patient does not have a history of substance abuse disorders. Potential treatment options for patients unresponsive to standard treatments are described in this overview. Although these guidelines focus on medications, non-pharmacological were also considered. Cognitive behavioural therapy (CBT) and other variants of behaviour therapy have been sufficiently investigated in controlled studies in patients with anxiety disorders, OCD, and PTSD to support them being recommended either alone or in combination with the above medicines.
    Full-text · Article · Feb 2008 · The World Journal of Biological Psychiatry
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To describe the course and outcome of patients with prospectively defined chronic mania and to identify predictors of treatment non-response. EMBLEM is a 2-year prospective, observational study of bipolar disorder treatment outcomes conducted in 14 European countries. Patients with a manic/mixed episode were assessed and prospectively followed for 1 year. Clinical scales (Clinical Global Impressions-Bipolar Disorder (CGI-BP) overall, mania, and depression; Young Mania Rating Scale (YMRS); and five-item Hamilton Depression Rating Scale (HAM-D-5)) and medication taken were systemically recorded. Treatment adherence and outcome measures were also captured. Chronic mania (non-response) was defined as not achieving more than one point improvement on CGI-BP mania scale during up to 12-month follow-up. The analysis was conducted with 3373 patients who had at least two CGI-BP mania ratings available. A total of 15% of patients fulfilled criteria for chronic mania. Compared to those who responded to treatment, chronic mania was associated with lower severity of mania symptoms at baseline (OR = 0.44, 95% CI 0.37-0.52), shorter duration of current episode before treatment start (OR = 0.71, 95% CI 0.52-0.96), more delusions/hallucinations at baseline (OR = 1.12, 95% CI 1.03-1.22), less socially active (OR = 0.52, 95% CI 0.39-0.70) and greater occupational impairment (OR = 1.54, 95% CI 1.01-2.35) by multivariate statistical analysis. Rather than severity or duration of manic symptoms, factors associated with chronicity in mania are the presence of psychotic symptoms and issues related to social and occupational functioning.
    Full-text · Article · Feb 2008 · The World Journal of Biological Psychiatry
Show more